Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI
Catheterization and Cardiovascular Interventions,  Clinical Article

Azmoon S et al. – The present article provides an overview of the literature on switching antiplatelet treatment strategies and practical considerations for the interventional cardiologist.

  • Dual antiplatelet therapy with aspirin plus a P2Y12 receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome (ACS) and in those undergoing percutaneous coronary intervention (PCI).
  • Clopidogrel is the most widely used P2Y12 receptor inhibitor.
  • Despite the clinical benefits associated with adjunctive clopidogrel therapy, a considerable number of patients continue to experience recurrent cardiovascular events.
  • Importantly, the interindividual response to clopidogrel is variable and is affected by multiple factors, including genetic polymorphisms and drugs that interfere with the conversion of clopidogrel to its active metabolite.
  • The individual variability to clopidogrel–induced antiplatelet effects has significant clinical implications that can result in an increased risk of atherothrombotic recurrences, including stent thrombosis.
  • The introduction of novel P2Y12 receptor inhibitors, such as prasugrel or ticagrelor, characterized by more potent and consistent platelet inhibitory effects, represent an opportunity for clinicians to consider these alternative therapies to overcome the limitations of clopidogrel.
  • Understanding the strategies and implications of switching antiplatelet treatment regimens is, therefore, key in the clinical setting.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

1 Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials Hypertension, September 29, 2014    Evidence Based Medicine    Review Article

2 Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation European Heart Journal, September 16, 2014    Clinical Article

3 Effects of tea intake on blood pressure: A meta-analysis of 21 randomized controlled trials JACC - Journal of the American College of Cardiology, October 22, 2014    Clinical Article

4 Chemicals found in everyday fruits could minimise organ damage after heart attack and stroke University of Cambridge News, November 14, 2014

5 PCI versus CABG: a meta-analysis The Journal of Thoracic and Cardiovascular Surgery, November 13, 2014    Clinical Article

6 Statins and almonds to lower lipoproteins (the STALL study) Journal of Clinical Lipidology, November 17, 2014

7 ‘Big data’ approach helps pinpoint possible new stent drug to prevent heart attacks Stanford School of Medicine News, November 20, 2014

8 What the guidelines do not say: statin non-benefit groups Current Atherosclerosis Reports, November 20, 2014    Clinical Guideline    Clinical Article

9 Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure Hypertension, November 25, 2014    Clinical Article

10 Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation International Journal of Cardiology, November 26, 2014    Clinical Article

11 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT Journal of the American Society of Hypertension, November 4, 2014    Clinical Article

12 Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy EP Europace, September 19, 2014    Clinical Article

13 Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents New England Journal of Medicine, November 19, 2014    Evidence Based Medicine    Clinical Article

14 Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysis Vascular Pharmacology, November 12, 2014    Clinical Article

15 The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: Results of a randomized trial American Heart Journal, October 1, 2014    Clinical Article

16 Meta-analysis on risk of bleeding with apixaban in patients with renal impairment The American Journal of Cardiology, November 21, 2014    Evidence Based Medicine    Review Article    Clinical Article

17 Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial Full Text Trials, November 18, 2014    Free full text    Evidence Based Medicine    Clinical Article

18 Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals International Journal of Cardiology, November 7, 2014    Clinical Article

19 Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials European Journal of Preventive Cardiology, November 26, 2014    Evidence Based Medicine    Review Article

20 A systematic review of statin-induced muscle problems in clinical trials American Heart Journal, October 7, 2014    Review Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore